Success of L-lysine therapy in frequently recurrent herpes s

Besvar
admin
Site Admin
Indlæg: 16
Tilmeldt: 24. jan 2008, 20:02

Success of L-lysine therapy in frequently recurrent herpes s

Indlæg af admin » 25. jan 2008, 13:05

Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis.

Kilde: pubmed.gov

Dermatologica. 1987;175(4):183-90.
Griffith RS, Walsh DE, Myrmel KH, Thompson RW, Behforooz A.
Department of Medicine, Indiana University School of Medicine, Indianapolis.

A double-blind, placebo-controlled, multicenter trial of oral L-lysine monohydrochloride for the prevention and treatment of recurrent herpes simplex (HSV) infection was conducted. The treatment group was given L-Lysine monohydrochloride tablets (1,000 mg L-lysine per dose) 3 times a day for 6 months. A total of 27 (6 male and 21 female) subjects on L-lysine and 25 (6 male and 19 female) subjects on placebo completed the trial. The L-lysine treatment group had an average of 2.4 (p less than 0.05) less HSV infections, symptoms were significantly (p less than 0.05) diminished in severity and healing time was significantly reduced (p less than 0.05). L-Lysine appears to be an effective agent for reduction of occurrence, severity and healing time for recurrent HSV infection.

Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis.
Oral Surg Oral Med Oral Pathol. 1984 Dec;58(6):659-66.
The amino acid lysine is an agent that has been proposed for treating the clinical symptoms of recurrent herpes simplex labialis. This study examined the efficacy of long-term prophylactic lysine supplementation. Twenty-six volunteers with a history of frequently recurring herpetic lesions completed a 12-month double-blind crossovers study. The experimental group received daily oral supplements of 1,000 mg 1-lysine. Serum samples were analyzed at scheduled intervals. In most instances, members of the lysine group reported significantly fewer lesions than the control group. Similarly, those who were taken off lysine supplementation generally showed a significant increase in lesion frequency. Quantitative hematologic measurements revealed the most clinically useful relationship. Data from this sample population indicated that when a person’s serum lysine concentration exceeded 165 nmol/ml there was a corresponding significant decrease in recurrence rate. Conversely, the frequency rate increased significantly as concentration levels fell below 165 nmol/ml. These results suggest that prophylactic lysine may be useful in managing selected cases of recurrent herpes simplex labialis if serum lysine levels can be maintained at adequate concentrations

Besvar